New markers and multivariate models for prostate cancer detection

Anticancer Research

Volumn 29, Issue 7, 2009, Pages 2589-2600

  Stephan, Carsten ^a   Rittenhouse, Harry ^b   Cammann, Henning ^a   Lein, Michael ^a,c   Schrader, Mark ^a   Deger, Serdar ^a   Miller, Kurt ^a   Jung, Klaus ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Gen Probe Incorporated   (United States)

^c Berlin Institute for Urologic Research   (Germany)

Author keywords

ANN; PCA3; Prostate cancer; PSA; Review

Indexed keywords

BETA MICROSEMINOPROTEIN; CAVEOLIN; GROWTH DIFFERENTIATION FACTOR 15; KALLIKREIN; MACROPHAGE MIGRATION INHIBITION FACTOR; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN C; TUMOR MARKER; TUMOR MARKER BPSA; TUMOR MARKER EPCA; TUMOR MARKER GOLM1; TUMOR MARKER PCA3; TUMOR MARKER TMPRSS2 ERG; UNCLASSIFIED DRUG;

ARTIFICIAL NEURAL NETWORK; CANCER DIAGNOSIS; DIGITAL RECTAL EXAMINATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; METHYLATION; MULTIVARIATE ANALYSIS; NOMOGRAM; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; URINALYSIS;

ANTIGENS, NEOPLASM; CAVEOLINS; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; KALLIKREINS; MALE; MULTIVARIATE ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SOMATOMEDINS; TUMOR MARKERS, BIOLOGICAL;

EID: 69249191526     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Aus G, Damber JE, Khatami A, Lilja H, Stranne J and Hugosson J: Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med 165: 1857-1861, 2005.
3. Postma R, Schroder FH, van Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ and van der Kwast TH: Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) - Section Rotterdam. A comparison of two rounds of screening. Eur Urol 52: 89-97, 2007.
4. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ and Coltman CA Jr: Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350: 2239-2246, 2004.
5. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M and Downs J: The prostate-specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? J Urol 172: 1297-1301, 2004.
6. Schroder FH, Roobol MJ, van der Kwast TH, Kranse R and Bangma CH: Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol 49: 460-465, 2006.
7. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL and Coltman CA Jr: Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98: 529-534, 2006. (Pubitemid 43898816)
8. Berger AP, Deibl M, Strasak A, Bektic J, Pelzer AE, Klocker H, Steiner H, Fritsche G, Bartsch G and Horninger W: Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer. Urology 69: 134-138, 2007. (Pubitemid 46161684)
9. Loeb S, Roehl KA, Catalona WJ and Nadler RB: Prostate-specific antigen velocity threshold for predicting prostate cancer in young men. J Urol 177: 899-902, 2007. (Pubitemid 46223578)
10. Mistry K and Cable G: Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract 16: 95-101, 2003.
11. Draisma G, Boer R, Otto SJ, van dC, I, Damhuis RA, Schroder FH and De Koning HJ: Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95: 868-878, 2003.
12. Vis AN, Hoedemaeker RF, Roobol M, Der Kwast TH and Schroder FH: Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml). Prostate 47: 252-261, 2001. (Pubitemid 32521744)
13. Lilja H, Ulmert D and Vickers AJ: Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 8: 268-278, 2008.
14. Loeb S and Catalona WJ: Prostate-specific antigen in clinical practice. Cancer Lett 249: 30-39, 2007.
15. Schroder FH, Carter HB, Wolters T, van den Bergh RC, Gosselaar C, Bangma CH and Roobol MJ: Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol 53: 468-477, 2008.
16. Stephan C, Buker N, Cammann H, Meyer HA, Lein M and Jung K: Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity. BMC Urol 8: 10, 2008.
17. Sardana G, Dowell B and Diamandis EP: Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem 54: 1951-1960, 2008.
18. Herawi M and Epstein JI: Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate. Am J Surg Pathol 31: 889-894, 2007. (Pubitemid 47165142)
19. Harden SV, Sanderson H, Goodman SN, Partin AA, Walsh PC, Epstein JI and Sidransky D: Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J Natl Cancer Inst 95: 1634-1637, 2003. (Pubitemid 37455931)
20. Reynolds MA, Kastury K, Groskopf J, Schalken JA and Rittenhouse H: Molecular markers for prostate cancer. Cancer Lett 249: 5-13, 2007.
21. Wright JL and Lange PH: Newer potential biomarkers in prostate cancer. Rev Urol 9: 207-213, 2007.
22. Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, Lonigro RJ, Tsodikov A, Wei JT, Tomlins SA and Chinnaiyan AM: A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 68: 645-649, 2008. (Pubitemid 351206738)
23. Vener T, Derecho C, Baden J, Wang H, Rajpurohit Y, Skelton J, Mehrotra J, Varde S, Chowdary D, Stallings W, Leibovich B, Robin H, Pelzer A, Schafer G, Auprich M, Mannweiler S, Amersdorfer P and Mazumder A: Development of a multiplexed urine assay for prostate cancer diagnosis. Clin Chem 54: 874-882, 2008. (Pubitemid 351671598)
24. Reynolds MA: Molecular alterations in prostate cancer. Cancer Lett 271: 13-24, 2008.
25. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA and Chinnaiyan AM: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648, 2005. (Pubitemid 41528150)
26. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R and Chinnaiyan AM: Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448: 595-599, 2007. (Pubitemid 47206938)
27. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE and Rubin MA: TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26: 4596-4599, 2007. (Pubitemid 47037039)
28. Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, Shah RB, Rubin MA, Wei JT and Chinnaiyan AM: Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 8: 885-888, 2006.
29. Morris DS, Tomlins SA, Montie JE and Chinnaiyan AM: The discovery and application of gene fusions in prostate cancer. BJU Int 102: 276-282, 2008. (Pubitemid 352019201)
30. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K and Alfthan O: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
31. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K and Lovgren T: Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 37: 1618-1625, 1991. (Pubitemid 21905228)
32. De Angelis G, Rittenhouse HG, Mikolajczyk SD, Blair SL and Semjonow A: Twenty years of PSA: from prostate antigen to tumor marker. Rev Urol 9: 113-123, 2007.
33. Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, Boccon-Gibod L and Ekman P: Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol Suppl pp. 64-81, 2005. (Pubitemid 40979094)
34. Stephan C, Jung K, Lein M and Diamandis EP: PSA and other tissue kallikreins for prostate cancer detection. Eur J Cancer 43: 1918-1926, 2007.
35. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL and Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
36. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG and Southwick PC: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279: 1542-1547, 1998.
37. Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Rannikko S and Stenman UH: Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. Clin Chem 44: 2471-2479, 1998. (Pubitemid 28565659)
38. Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S and Stenman UH: Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum. Clin Chem 45: 814-821, 1999. (Pubitemid 29266611)
39. Allard WJ, Zhou Z and Yeung KK: Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 44: 1216-1223, 1998. (Pubitemid 28283059)
40. Brawer MK, Meyer GE, Letran JL, Bankson ER, Morris DL, Yeung KK and Allard WJ: Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 52: 372-378, 1998.
41. Lein M, Kwiatkowski M, Semjonow A, Luboldt HJ, Hammerer P, Stephan C, Klevecka V, Taymoorian K, Schnorr D, Recker F, Loening SA and Jung K: A multicenter clinical trial on the use of complexed prostate-specific antigen in low prostate specific antigen concentrations. J Urol 170: 1175-1179, 2003. (Pubitemid 37108106)
42. Stephan C, Schnorr D, Loening SA and Jung K: Re: Roddam AW, Duffy MJ, Hamdy FC et al: Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. (Eur Urol 48: 386-399, 2005). Eur Urol 48: 1059-1060, 2005.
43. Mikolajczyk SD, Grauer LS, Millar LS, Hill TM, Kumar A, Rittenhouse HG, Wolfert RL and Saedi MS: A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 50: 710-714, 1997. (Pubitemid 27494991)
44. Peter J, Unverzagt C, Krogh TN, Vorm O and Hoesel W: Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 61: 957-962, 2001. (Pubitemid 32174411)
45. Bangma CH, Wildhagen MF, Yurdakul G, Schroder FH and Blijenberg BG: The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int 93: 720-724, 2004. (Pubitemid 38497017)
46. Lein M, Semjonow A, Graefen M, Kwiatkowski M, Abramjuk C, Stephan C, Haese A, Chun F, Schnorr D, Loening SA and Jung K: A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. J Urol 174: 2150-2153, 2005. (Pubitemid 41611761)
47. Stephan C, Meyer HA, Paul EM, Kristiansen G, Loening SA, Lein M and Jung K: Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer. Anticancer Res 27: 1833-1836, 2007.
48. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Amirkhan A, Horninger W, Klocker H and Mikolajczyk SD: Serum proprostate-specific antigen improves cancer detection compared to free and complexed prostate-specific antigen in men with prostate-specific antigen 2 to 4 ng/ml. J Urol 170: 2181-2185, 2003. (Pubitemid 37413952)
49. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Horninger W, Klocker H and Mikolajczyk SD: Serum proprostate-specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate-specific antigen. J Urol 171: 2239-2244, 2004. (Pubitemid 38625443)
50. Sokoll LJ, Wang Y, Feng Z, Kagan J, Partin AW, Sanda MG, Thompson IM and Chan DW: (-2)proenzyme prostate-specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol 180: 539-543, 2008.
51. Mikolajczyk SD and Rittenhouse HG: Pro PSA: a more cancer specific form of prostate-specific antigen for the early detection of prostate cancer. Keio J Med 52: 86-91, 2003. (Pubitemid 36834402)
52. Peyromaure M, Fulla Y, Debre B and Dinh-Xuan AT: Pro PSA: a "pro cancer" form of PSA? Med Hypotheses 64: 92-95, 2005.
53. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Wolfert RL, Marks LS, Song W, Wheeler TM and Slawin KM: "BPSA", a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 55: 41-45, 2000.
54. Wang TJ, Slawin KM, Rittenhouse HG, Millar LS and Mikolajczyk SD: Benign prostatic hyperplasia-associated prostate-specific antigen (BPSA) shows unique immunoreactivity with anti-PSA monoclonal antibodies. Eur J Biochem 267: 4040-4045, 2000.
55. Canto EI, Singh H, Shariat SF, Lamb DJ, Mikolajczyk SD, Linton HJ, Rittenhouse HG, Kadmon D, Miles BJ and Slawin KM: Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 63: 905-910, 2004. (Pubitemid 38596676)
56. Linton HJ, Marks LS, Millar LS, Knott CL, Rittenhouse HG and Mikolajczyk SD: Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem 49: 253-259, 2003. (Pubitemid 36143447)
57. Slawin KM, Shariat S and Canto E: BPSA: A Novel Serum Marker for Benign Prostatic Hyperplasia. Rev Urol 7(Suppl 8): S52-S56, 2005.
58. Stephan C, Cammann H, Lein M, Schrader M, Deger S, Miller K and Jung K: BPHA (bPSA) improves detection of prostate cancer in an artificial neural network. Urology: in press 2009.
59. de Vries SH, Raaijmakers R, Blijenberg BG, Mikolajczyk SD, Rittenhouse HG and Schroder FH: Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer. Urology 65: 926-930, 2005.
60. Mikolajczyk SD, Marks LS, Partin AW and Rittenhouse HG: Free prostate-specific antigen in serum is becoming more complex. Urology 59: 797-802, 2002.
61. Nurmikko P, Vaisanen V, Piironen T, Lindgren S, Lilja H and Pettersson K: Production and characterization of novel antiprostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA. Clin Chem 46: 1610-1618, 2000. (Pubitemid 30776626)
62. Nurmikko P, Pettersson K, Piironen T, Hugosson J and Lilja H: Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin Chem 47: 1415-1423, 2001. (Pubitemid 32678820)
63. Steuber T, Nurmikko P, Haese A, Pettersson K, Graefen M, Hammerer P, Huland H and Lilja H: Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate-specific antigen. J Urol 168: 1917-1922, 2002.
64. Yousef GM and Diamandis EP: The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 22: 184-204, 2001. (Pubitemid 32458158)
65. Lundwall A, Band V, Blaber M, Clements JA, Courty Y, Diamandis EP, Fritz H, Lilja H, Malm J, Maltais LJ, Olsson AY, Petraki C, Scorilas A, Sotiropoulou G, Stenman UH, Stephan C, Talieri M and Yousef GM: A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem 357: 637-641, 2006. (Pubitemid 43964785)
66. Kwiatkowski MK, Recker F, Piironen T, Pettersson K, Otto T, Wernli M and Tscholl R: In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Urology 52: 360-365, 1998.
67. Partin AW, Catalona WJ, Finlay JA, Darte C, Tindall DJ, Young CY, Klee GG, Chan DW, Rittenhouse HG, Wolfert RL and Woodrum DL: Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology 54: 839-845, 1999. (Pubitemid 29505583)
68. Nakamura T, Scorilas A, Stephan C, Jung K, Scosaipillai AR and Diamandis EP: The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res 63: 6543-6546, 2003. (Pubitemid 37255209)
69. Brown DA, Stephan C, Ward RL, Law M, Hunter M, Bauskin AR, Amin J, Jung K, Diamandis EP, Hampton GM, Russell PJ, Giles GG and Breit SN: Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res 12: 89-96, 2006. (Pubitemid 43166181)
70. Stephan C, Xu C, Brown DA, Breit SN, Michael A, Nakamura T, Diamandis EP, Meyer H, Cammann H and Jung K: Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate 66: 651-659, 2006.
71. Meyer-Siegler KL, Bellino MA and Tannenbaum M: Macrophage migration inhibitory factor evaluation compared with prostate-specific antigen as a biomarker in patients with prostate carcinoma. Cancer 94: 1449-1456, 2002.
72. Michael A, Stephan C, Kristiansen G, Burckhardt M, Loening SA, Schnorr D and Jung K: Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation. Prostate 62: 34-39, 2005. (Pubitemid 39614291)
73. Tahir SA, Ren C, Timme TL, Gdor Y, Hoogeveen R, Morrisett JD, Frolov A, Ayala G, Wheeler TM and Thompson TC: Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res 9: 3653-3659, 2003. (Pubitemid 37169231)
74. Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP, Wheeler TM, Ayala G, Thompson TC and Kadmon D: Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res 12: 4872-4875, 2006. (Pubitemid 44338573)
75. Paul B, Dhir R, Landsittel D, Hitchens MR and Getzenberg RH: Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res 65: 4097-4100, 2005. (Pubitemid 40775646)
76. Leman ES, Cannon GW, Trock BJ, Sokoll LJ, Chan DW, Mangold L, Partin AW and Getzenberg RH: EPCA-2: a highly specific serum marker for prostate cancer. Urology 69: 714-720, 2007. (Pubitemid 46574950)
77. Diamandis EP: POINT: EPCA-2: a promising new serum biomarker for prostatic carcinoma? Clin Biochem 40: 1437-1439, 2007.
78. Leman ES, Magheli A, Cannon GW, Sokoll LJ, Chan DW, Mangold L, Partin AW and Getzenberg RH: Analysis of a second EPCA-2 epitope as a serum test for prostate cancer. J Urol (Suppl) 179: 704, 2008.
79. Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G and Kaaks R: High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 22: 3104-3112, 2004. (Pubitemid 41103723)
80. Finne P, Auvinen A, Koistinen H, Zhang WM, Maattanen L, Rannikko S, Tammela T, Seppala M, Hakama M and Stenman UH: Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab 85: 2744-2747, 2000. (Pubitemid 32269145)
81. Oliver SE, Holly J, Peters TJ, Donovan J, Persad R, Gillatt D, Pearce A, Hamdy FC, Neal DE and Gunnell D: Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening. Urology 64: 317-322, 2004. (Pubitemid 39092463)
82. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV Jr, Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF, Schroder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, Quesenberry CP Jr, Vogelman JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan J, Meyer F, Bairati I and Galan P: Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149: 461-468, 2008.
83. von der Kammer H, Jurincic-Winkler C, Horlbeck R, Klippel KF, Pixberg HU and Scheit KH: The potential use of prostatic secretory protein of 94 amino acid residues (PSP94) as a serum marker for prostatic tumor. Urol Res 21: 227-233, 1993. (Pubitemid 23253442)
84. Nam RK, Reeves JR, Toi A, Dulude H, Trachtenberg J, Emami M, Daigneault L, Panchal C, Sugar L, Jewett MA and Narod SA: A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. J Urol 175: 1291-1297, 2006. (Pubitemid 43312972)
85. Reeves JR, Dulude H, Panchal C, Daigneault L and Ramnani DM: Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. Clin Cancer Res 12: 6018-6022, 2006. (Pubitemid 44703763)
86. Wozny W, Schroer K, Schwall GP, Poznanovic S, Stegmann W, Dietz K, Rogatsch H, Schaefer G, Huebl H, Klocker H, Schrattenholz A and Cahill MA: Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: cancer association of annexin A3. Proteomics 7: 313-322, 2007. (Pubitemid 46184093)
87. Kollermann J, Schlomm T, Bang H, Schwall GP, von Eichel-Streiber C, Simon R, Schostak M, Huland H, Berg W, Sauter G, Klocker H and Schrattenholz A: Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol 54: 1314-1323, 2008.
88. Schostak M, Schwall GP, Poznanovic S, Groebe K, Muller M, Messinger D, Miller K, Krause H, Pelzer A, Horninger W, Klocker H, Hennenlotter J, Feyerabend S, Stenzl A and Schrattenholz A: Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol 181: 343-353, 2009.
89. Hessels D, Klein Gunnewiek JM, van O, I, Karthaus HF, van Leenders GJ, van BB, Kiemeney LA, Witjes JA and Schalken JA: DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44: 8-15, 2003. (Pubitemid 36741368)
90. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS and Rittenhouse H: APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52: 1089-1095, 2006. (Pubitemid 43794421)
91. Haese A, de la TA, van PH, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP and Schalken JA: Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54: 1081-1088, 2008.
92. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse H and Babaian RJ: PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 179: 1804-1809, 2008.
93. Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, Petrovics G, Ibrahim M, Elsamanoudi S, Cullen J, Sesterhenn IA, Brassell S, Rittenhouse H, Srivastava S and McLeod DG: PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 180: 1975-1978, 2008.
94. van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, Witjes JA, Jansen CF, Mulders PF, Rittenhouse HG and Schalken JA: Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 68: 1215-1222, 2008.
95. Varambally S, Laxman B, Mehra R, Cao Q, Dhanasekaran SM, Tomlins SA, Granger J, Vellaichamy A, Sreekumar A, Yu J, Gu W, Shen R, Ghosh D, Wright LM, Kladney RD, Kuefer R, Rubin MA, Fimmel CJ and Chinnaiyan AM: Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia 10: 1285-1294, 2008.
96. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C and Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457: 910-914, 2009.
97. Jung K: Re: The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. European Urology 54: 1198-1199, 2008.
98. Chun FK, Karakiewicz PI, Briganti A, Walz J, Kattan MW, Huland H and Graefen M: A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancer. BJU Int 99: 794-800, 2007. (Pubitemid 46439569)
99. Hernandez DJ, Han M, Humphreys EB, Mangold LA, Taneja SS, Childs SJ, Bartsch G and Partin AW: Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone. BJU Int online available: 2008.
100. Shariat SF, Capitanio U, Jeldres C and Karakiewicz PI: Can nomograms be superior to other prediction tools? BJU Int online available: 2008.
101. Chun FK, Graefen M, Briganti A, Gallina A, Hopp J, Kattan MW, Huland H and Karakiewicz PI: Initial biopsy outcome prediction-head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol 51: 1236-1240, 2007. (Pubitemid 46436287)
102. Finne P, Finne R, Bangma C, Hugosson J, Hakama M, Auvinen A and Stenman UH: Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening. Int J Cancer 111: 310-315, 2004. (Pubitemid 38924712)
103. Kawakami S, Numao N, Okubo Y, Koga F, Yamamoto S, Saito K, Fujii Y, Yonese J, Masuda H, Kihara K and Fukui I: Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy. Eur Urol 54: 601-611, 2008.
104. Djavan B, Remzi M, Zlotta A, Seitz C, Snow P and Marberger M: Novel artificial neural network for early detection of prostate cancer. J Clin Oncol 20: 921-929, 2002. (Pubitemid 34141833)
105. Finne P, Finne R, Auvinen A, Juusela H, Aro J, Maattanen L, Hakama M, Rannikko S, Tammela TL and Stenman U: Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perception network. Urology 56: 418-422, 2000. (Pubitemid 30658171)
106. Kalra P, Togami J, Bansal BSG, Partin AW, Brawer MK, Babaian RJ, Ross LS and Niederberger CS: A neurocomputational model for prostate carcinoma detection. Cancer 98: 1849-1854, 2003.
107. Dreiseitl S and Ohno-Machado L: Logistic regression and artificial neural network classification models: a methodology review. J Biomed Inform 35: 352-359, 2002. (Pubitemid 36951935)
108. Sargent DJ: Comparison of artificial neural networks with other statistical approaches. Cancer 91: 1636-1642, 2001.
109. Stephan C, Meyer HA, Cammann H, Lein M, Loening SA and Jung K: Re: Chun FKH, Graefen M, Briganti A, Gallina A, HoppJ, Kattan MW, Huland H and Karakiewicz PI. Initial biopsy outcome prediction - head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol 51: 1236-1243, 2007.
110. Eur Urol 51: 1446-1447, 2007.
111. Snow PB, Smith DS and Catalona WJ: Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. J Urol 152: 1923-1926, 1994.
112. Babaian RJ, Fritsche H, Ayala A, Bhadkamkar V, Johnston DA, Naccarato W and Zhang Z: Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL. Urology 56: 1000-1006, 2000.
113. Stephan C, Jung K, Cammann H, Vogel B, Brux B, Kristiansen G, Rudolph B, Hauptmann S, Lein M, Schnorr D, Sinha P and Loening SA: An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: Results of a 5-year investigation. Int J Cancer 99: 466-473, 2002. (Pubitemid 34495864)
114. Stephan C, Cammann H, Meyer HA, Lein M and Jung K: PSA and new biomarkers within multivariate models to improve early detection of prostate cancer. Cancer Lett 249: 18-29, 2007. (Pubitemid 46428002)
115. Schroder F and Kattan MW: The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: A Systematic Review. Eur Urol 54: 274-290, 2008.
116. Stephan C, Cammann H, Meyer HA, Muller C, Deger S, Lein M and Jung K: An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics. BJU Int 102: 799-805, 2008.
117. Stephan C, Xu C, Cammann H, Graefen M, Haese A, Huland H, Semjonow A, Diamandis EP, Remzi M, Djavan B, Wildhagen MF, Blijenberg BG, Finne P, Stenman UH, Jung K and Meyer HA: Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men. World J Urol 25: 95-103, 2007.
118. Stephan C, Xu C, Finne P, Cammann H, Meyer HA, Lein M, Jung K and Stenman UH: Comparison of two different artificial neural networks for prostate biopsy indication in two different patient populations. Urology 70: 596-601, 2007. (Pubitemid 47464478)
119. Keller T, Butz H, Lein M, Kwiatkowski M, Semjonow A, Luboldt HJ, Hammerer P, Stephan C and Jung K: Discordance analysis characteristics as a new method to compare the diagnostic accuracy of tests: example of complexed versus total prostate-specific antigen. Clin Chem 51: 532-539, 2005. (Pubitemid 40300228)
120. Stephan C, Meyer HA, Kwiatkowski M, Recker F, Cammann H, Loening SA, Jung K and Lein M: A (-5, -7) ProPSA-based artificial neural network to detect prostate cancer. Eur Urol 50: 1014-1020, 2006. (Pubitemid 44508781)
121. Stephan C, Kahrs AM, Cammann H, Lein M, Schrader M, Deger S, Miller K and Jung K: A (-2)proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 69: 198-207, 2009.
122. Vickers AJ, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K, Scardino PT, Hugosson J and Lilja H: A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med 6: 19, 2008.
123. Stephan C, Jung K, Soosaipillai A, Yousef GM, Cammann H, Meyer H, Xu C and Diamandis EP: Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. BJU Int 96: 521-527, 2005. (Pubitemid 41224320)
124. Stephan C, Meyer HA, Cammann H, Nakamura T, Diamandis EP and Jung K: Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network. Biol Chem 357: 801-805, 2006. (Pubitemid 43964804)
125. Emami N and Diamandis EP: Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin Chem 54: 1600-1607, 2008.
126. Parekh DJ, Ankerst DP, Troyer D, Srivastava S and Thompson IM: Biomarkers for prostate cancer detection. J Urol 178: 2252-2259, 2007.
127. Scorilas A, Plebani M, Mazza S, Basso D, Soosaipillai AR, Katsaros N, Pagano F and Diamandis EP: Serum human glandular kallikrein (hK2) and
128. Zhigang Z, Jieming L, Su L and Wenlu S: Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml. J Surg Oncol 96: 54-61, 2007. (Pubitemid 47015449)
129. Aubin SM, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Hessels D, Schalken J, Rittenhouse H and Groskopf J: Improved prediction of prostate biopsy outcome using PCA3, TMPRSS2:ERG gene fusion and serum PSA. J Urol Suppl 179: 725, 2008.
130. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB and Schalken JA: Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 13: 5103-5108, 2007. (Pubitemid 47502077)